These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 38963046

  • 21. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
    Bashash D, Delshad M, Riyahi N, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Momeny M.
    Eur J Pharmacol; 2018 Dec 15; 841():10-18. PubMed ID: 30316766
    [Abstract] [Full Text] [Related]

  • 22. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
    Golemovic M, Quintás-Cardama A, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S.
    Invest New Drugs; 2010 Aug 15; 28(4):402-12. PubMed ID: 19468689
    [Abstract] [Full Text] [Related]

  • 23. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
    Esmaeili S, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Salari S, Gharehbaghian A, Hamidpour M, Bashash D.
    Int J Biochem Cell Biol; 2020 May 15; 122():105739. PubMed ID: 32169580
    [Abstract] [Full Text] [Related]

  • 24. BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
    Tanaka Y, Komatsu T, Shigemi H, Yamauchi T, Fujii Y.
    BMC Cancer; 2014 Jan 15; 14():27. PubMed ID: 24428916
    [Abstract] [Full Text] [Related]

  • 25. Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4.
    Yaghmaie M, Mozdarani H, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A, Hajhashemi M.
    Med Oncol; 2012 Jun 15; 29(2):1209-16. PubMed ID: 21544632
    [Abstract] [Full Text] [Related]

  • 26. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
    Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K, Liu Y.
    Cancer Lett; 2009 Nov 01; 284(2):208-15. PubMed ID: 19457607
    [Abstract] [Full Text] [Related]

  • 27. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.
    Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J.
    Med Oncol; 2011 Mar 01; 28(1):211-8. PubMed ID: 20143188
    [Abstract] [Full Text] [Related]

  • 28. Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
    Iriyama N, Yuan B, Yoshino Y, Hatta Y, Horikoshi A, Aizawa S, Takeuchi J, Toyoda H.
    Oncol Rep; 2013 Jun 01; 29(6):2362-8. PubMed ID: 23563754
    [Abstract] [Full Text] [Related]

  • 29. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Zhang T, Ma D, Wei D, Lu T, Yu K, Zhang Z, Wang W, Fang Q, Wang J.
    Anticancer Drugs; 2020 Feb 01; 31(2):158-168. PubMed ID: 31584454
    [Abstract] [Full Text] [Related]

  • 30. Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis.
    Jamil M, Mohammadi-Bardbori A, Safa O, Nikpoor AR, Bakhtari A, Mokhtarinejad M, Zadeh SN, Shadboorestan A, Omidi M.
    Drug Res (Stuttg); 2023 Sep 01; 73(7):417-425. PubMed ID: 37230480
    [Abstract] [Full Text] [Related]

  • 31. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
    Maimaitiyiming Y, Zhu HH, Yang C, Naranmandura H.
    Drug Metab Rev; 2020 Aug 01; 52(3):425-437. PubMed ID: 32677488
    [Abstract] [Full Text] [Related]

  • 32. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
    Kumar S, Yedjou CG, Tchounwou PB.
    J Exp Clin Cancer Res; 2014 May 16; 33(1):42. PubMed ID: 24887205
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
    Sánchez Y, Simón GP, Calviño E, de Blas E, Aller P.
    J Pharmacol Exp Ther; 2010 Oct 16; 335(1):114-23. PubMed ID: 20605902
    [Abstract] [Full Text] [Related]

  • 35. Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.
    Doudican NA, Bowling B, Orlow SJ.
    Leuk Res; 2010 Feb 16; 34(2):229-34. PubMed ID: 19540589
    [Abstract] [Full Text] [Related]

  • 36. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
    Bashash D, Ghaffari SH, Zaker F, Kazerani M, Hezave K, Hassani S, Rostami M, Alimoghaddam K, Ghavamzadeh A.
    Anticancer Agents Med Chem; 2013 Sep 16; 13(7):1115-25. PubMed ID: 23293885
    [Abstract] [Full Text] [Related]

  • 37. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
    Liu ZM, Tseng HY, Cheng YL, Yeh BW, Wu WJ, Huang HS.
    Toxicol Appl Pharmacol; 2015 May 15; 285(1):41-50. PubMed ID: 25791921
    [Abstract] [Full Text] [Related]

  • 38. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
    Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, Krishna S, Korula A, Kulkarni U, Janet NB, Balasubramanian P, Mathews V.
    Blood Adv; 2022 Jan 25; 6(2):652-663. PubMed ID: 34625794
    [Abstract] [Full Text] [Related]

  • 39. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
    Zaki Dizaji M, Ghaffari SH, Hosseini E, Alizadeh N, Rostami S, Momeny M, Alimoghaddam K, Ghavamzadeh A.
    Asia Pac J Clin Oncol; 2017 Apr 25; 13(2):e21-e30. PubMed ID: 27770503
    [Abstract] [Full Text] [Related]

  • 40. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
    Giansanti M, De Gabrieli A, Prete SP, Ottone T, Divona MD, Karimi T, Ciccarone F, Voso MT, Graziani G, Faraoni I.
    J Pharmacol Exp Ther; 2021 Jun 25; 377(3):385-397. PubMed ID: 33820831
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.